Goblet cell replacement therapy
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsCecelia C. Yates-Binder, Alan H. Wells, Joel S. Schuman, Ian P. Conner
Life of this patent
Estimating the term…
Abstract
Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.
Claims26
A method for increasing goblet cell density in epithelial tissue of a subject, comprising administering to the subject a therapeutically effective amount of an activator of CXCR3, thereby increasing goblet cell density in the subject.
6-7. (canceled)
11-12. (canceled)
15-16. (canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.